301 related articles for article (PubMed ID: 12192082)
1. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.
Kokoris MS; Black ME
Protein Sci; 2002 Sep; 11(9):2267-72. PubMed ID: 12192082
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy.
Kokoris MS; Sabo P; Black ME
Anticancer Res; 2000; 20(2A):959-63. PubMed ID: 10810381
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing.
Black ME; Kokoris MS; Sabo P
Cancer Res; 2001 Apr; 61(7):3022-6. PubMed ID: 11306482
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.
Kokoris MS; Sabo P; Adman ET; Black ME
Gene Ther; 1999 Aug; 6(8):1415-26. PubMed ID: 10467366
[TBL] [Abstract][Full Text] [Related]
5. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.
Black ME; Newcomb TG; Wilson HM; Loeb LA
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3525-9. PubMed ID: 8622970
[TBL] [Abstract][Full Text] [Related]
6. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.
Gustafson EA; Chillemi AC; Sage DR; Fingeroth JD
Antimicrob Agents Chemother; 1998 Nov; 42(11):2923-31. PubMed ID: 9797227
[TBL] [Abstract][Full Text] [Related]
7. A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs.
Likar Y; Dobrenkov K; Olszewska M; Vider E; Shenker L; Cai S; Pillarsetty N; Hricak H; Ponomarev V
J Nucl Med; 2008 May; 49(5):713-20. PubMed ID: 18413388
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
9. Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities.
Hinds TA; Compadre C; Hurlburt BK; Drake RR
Biochemistry; 2000 Apr; 39(14):4105-11. PubMed ID: 10747801
[TBL] [Abstract][Full Text] [Related]
10. A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing.
McSorley T; Ort S; Monnerjahn C; Konrad M
Biochem Pharmacol; 2014 Feb; 87(3):435-44. PubMed ID: 24316433
[TBL] [Abstract][Full Text] [Related]
11. Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies.
Mercer KE; Ahn CE; Coke A; Compadre CM; Drake RR
Protein Eng; 2002 Nov; 15(11):903-11. PubMed ID: 12538910
[TBL] [Abstract][Full Text] [Related]
12. Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1.
Bae PK; Kim JH; Kim HS; Chung IK; Paik SG; Lee CK
Antiviral Res; 2006 Jul; 70(3):93-104. PubMed ID: 16546268
[TBL] [Abstract][Full Text] [Related]
13. Contribution of a combination of ponicidin and acyclovir/ganciclovir to the antitumor efficacy of the herpes simplex virus thymidine kinase gene therapy system.
Hayashi K; Hayashi T; Sun HD; Takeda Y
Hum Gene Ther; 2002 Feb; 13(3):415-23. PubMed ID: 11860708
[TBL] [Abstract][Full Text] [Related]
14. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
15. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine.
Degrève B; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2000 Dec; 58(6):1326-32. PubMed ID: 11093770
[TBL] [Abstract][Full Text] [Related]
16. The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase.
Balzarini J; Liekens S; Esnouf R; De Clercq E
Biochemistry; 2002 May; 41(20):6517-24. PubMed ID: 12009916
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human papillomavirus (HPV) type 16-infected cells using herpes simplex virus type 1 thymidine kinase-mediated gene therapy transcriptionally regulated by the HPV E2 protein.
Sethi N; Palefsky J
Hum Gene Ther; 2003 Jan; 14(1):45-57. PubMed ID: 12573058
[TBL] [Abstract][Full Text] [Related]
18. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells.
Balzarini J; Degrève B; Andrei G; Neyts J; Sandvold M; Myhren F; de Clercq E
Gene Ther; 1998 Mar; 5(3):419-26. PubMed ID: 9614564
[TBL] [Abstract][Full Text] [Related]
19. Substrate specificity and molecular modelling of the feline herpesvirus-1 thymidine kinase.
Hussein IT; Miguel RN; Tiley LS; Field HJ
Arch Virol; 2008; 153(3):495-505. PubMed ID: 18196203
[TBL] [Abstract][Full Text] [Related]
20. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing.
Willmon CL; Krabbenhoft E; Black ME
Gene Ther; 2006 Sep; 13(17):1309-12. PubMed ID: 16810197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
